Why do we innovate?
PRoPosit Bio is a SME that was founded with the goal of carrying out research and Innovating in the Areas of Transfusion, Hemotherapy and Cell Therapy, and It has made good on some of the ideas of its founder, a hematologist MD with 25 year of experience in these fields.
The first project developed by our Company was the “PRoPosit method” to obtain platelet rich plasma (PRP) for non-transfusional clinical use. This project has been on the market since 2014, and more than 400 patients have been treated with our protocol. More information on this project is available on our website. From that experience, PRoPosit developed a hemotherapy project in the veterinary field with two partners. See “ProPosit Vet”.
Recently, the development of a new transfusional safety system, named “The Para-T system” has boosted our R&D department, especially after the grant obtained in February 2018 as part of the Horizon 2020 Framework Programme SME Phase I. For more information on this project, please go to the “The Para-T transfusional safety project”.
The Para-T system project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No H2020-SMEINST-816466
El plasma Rico en plaquetas (PRP) es un componente sanguíneo preparado a partir de la sangre de un donante o un paciente.
PRoPosit Bio is a SME that was founded with the goal of carrying out research and Innovating in the Areas of Transfusion, Hemotherapy and Cell Therapy